Compare LAW & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LAW | BNTC |
|---|---|---|
| Founded | 2013 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 274.2M | 411.4M |
| IPO Year | 2021 | 2020 |
| Metric | LAW | BNTC |
|---|---|---|
| Price | $3.80 | $11.43 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $8.00 | ★ $27.67 |
| AVG Volume (30 Days) | ★ 466.9K | 87.4K |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 22.58 | ★ 80.94 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $156,849,000.00 | N/A |
| Revenue This Year | $11.23 | N/A |
| Revenue Next Year | $10.60 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 8.29 | N/A |
| 52 Week Low | $2.45 | $9.85 |
| 52 Week High | $9.11 | $17.15 |
| Indicator | LAW | BNTC |
|---|---|---|
| Relative Strength Index (RSI) | 45.34 | 40.57 |
| Support Level | $3.30 | $11.40 |
| Resistance Level | $4.94 | $13.27 |
| Average True Range (ATR) | 0.36 | 0.66 |
| MACD | -0.09 | -0.14 |
| Stochastic Oscillator | 24.13 | 22.30 |
CS Disco Inc provides a cloud-native, artificial intelligence-powered legal solution that simplifies discovery, legal document review, and case management for enterprises, law firms, legal services providers, and governments. Its revenue-generating activities directly relate to the sale and support of legal solutions. It has two primary types of contractual arrangements: usage-based and subscription solutions. The usage-based revenue is derived from contracts under which customers are billed monthly based on their usage. Subscription revenue is derived from contracts where customers are contractually committed to a minimum data volume over a period of time.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.